MétaCan
Menu
Back to cohort
Record W4416282516 · doi:10.2196/69525

Evaluation of the ALIBIRD mHealth Platform for Care of Patients With Lung Cancer: Prospective Pilot Study

2025· article· en· W4416282516 on OpenAlexvenueno aff
Jose M. Iniesta-Chamorro, María Sereno, Beatriz Garrido-Rubiales, Isabel Espinosa‐Salinas, Juan Moreno‐Rubio, Beatriz Tabarés, Irene Hernández de Córdoba, María Morales, Natalia Molinero, M. Victoria Moreno‐Arribas, Guillermo Reglero, Ana Ramı́rez de Molina, Enrique J. Gómez Aguilera, Enrique Casado

Bibliographic record

VenueJMIR Cancer · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer survivorship and care
Canadian institutionsnot available
FundersAgencia Estatal de InvestigaciónEuropean CommissionEuropean Regional Development FundComunidad de Madrid
KeywordsmHealthDigital healthTelemedicineHealth careMEDLINEProspective cohort study

Abstract

fetched live from OpenAlex

Background: Mobile health (mHealth) represents a promising instrument for optimizing symptom management and important lifestyle strategies that enhance self-care and the quality of health care for patients with cancer. The ALIBIRD mHealth platform is a digital health solution specifically designed for the telemonitoring of oncology patients, fostering patient empowerment and supporting clinical decision-making. Objective: The primary objective of this study was to evaluate the patient experience with the ALIBIRD platform. In addition, the study aimed to assess clinical outcomes, particularly in symptom management, nutritional status, and lifestyle, using patient-reported outcome measures (PROMs). Methods: The evaluation was conducted over a 30-week period in patients with advanced lung cancer receiving active treatment. Outcome variables included usability, patient experience, symptom burden, lifestyle behaviors (diet, physical activity, and sleep), nutritional status, PROMs, and system-generated clinical alerts. Through the mobile app, patients reported symptoms and completed integrated REDCap (Research Electronic Data Capture) questionnaires assessing lifestyle behaviors and PROMs, while receiving personalized recommendations informed by nutrigenetic and gut microbiota assessments. Daily activity and sleep data were automatically captured using the Fitbit Inspire wearable. Clinicians remotely monitored patient data using a web-based dashboard and performed clinical actions when required, including phone calls, therapeutic adjustments, referrals, and appointment rescheduling. Statistical analysis included descriptive summaries and pre-post comparisons of clinical and patient-reported outcomes. Results: Out of 20 patients recruited for the study, 14 completed the intervention. The System Usability Scale yielded a score of 90, indicating high usability. Among the 14 completers, adherence to scheduled questionnaires ranged from 94% to 100% for several instruments, and wearable-based monitoring ranged from 66% to 96% across visits. Overall, the ALIBIRD platform collected and processed 3589 patient-reported outcomes related to physical activity, 3468 related to sleep, 679 on-demand symptom entries, and 1524 completed questionnaires. Clinically, 143 alerts were resolved within an average of 2.05 days, resulting in 2 referrals to emergency rooms and 2 early detections of disease progressions. Furthermore, more than 2100 personalized recommendations contributed to a 21% (3/14 patients) increase in adherence to the Mediterranean diet and a 14% (2/14 patients) increase in moderate physical activity. Conclusions: The evaluation of the ALIBIRD implementation yielded promising results in that it facilitated the adoption of healthier lifestyle habits while enhancing health self-management among oncology patients. The ALIBIRD mHealth platform emerges as an effective digital health tool that enables closer monitoring of patients and thereby more informed clinical decision-making.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.044

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.011
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.382
Teacher spread0.350 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJMIR CancerSame topicCancer survivorship and careFrench-language works237,207